HanAll Biopharma Submits IND for Second Phase 3 (VELOS-3) of..
HanAll\'s Partner HBM Announces Positive Topline Results from Phase 2 of Batoclimab in MG
2021.07.07
HanAll Biopharma (KRX: 009420.KS) today announced that its partner for HL161 (batoclimab) & HL036 (tanfanercept), Harbour BioMed, reported positive topline results from Phase 2 of batoclimab in MG.
- HBM press release link: https://www.harbourbiomed.com/news/157.html